clinical trial · NCT04703920
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center·phase1·completed·n = 26
Metastatic Breast CancerMetastatic Castration-resistant Prostate CancerMetastatic Ovarian CarcinomaMetastic or Unresectable Pancreatic AdenocarcinomaTalazoparibBelinostat
brief summary
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.
started
Mar 4, 2021
primary completion
Dec 1, 2024
completion
Jan 2, 2025
last updated
Jan 23, 2025
official title
A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol